| Literature DB >> 36106051 |
Mayowa M Ojo1,2, Temitope O Benson3, Olumuyiwa James Peter4,5, Emile Franc Doungmo Goufo2.
Abstract
Infectious diseases have remained one of humanity's biggest problems for decades. Multiple disease infections, in particular, have been shown to increase the difficulty of diagnosing and treating infected people, resulting in worsening human health. For example, the presence of influenza in the population is exacerbating the ongoing COVID-19 pandemic. We formulate and analyze a deterministic mathematical model that incorporates the biological dynamics of COVID-19 and influenza to effectively investigate the co-dynamics of the two diseases in the public. The existence and stability of the disease-free equilibrium of COVID-19-only and influenza-only sub-models are established by using their respective threshold quantities. The result shows that the COVID-19 free equilibrium is locally asymptotically stable when R C < 1 , whereas the influenza-only model, is locally asymptotically stable when R F < 1 . Furthermore, the existence of the endemic equilibria of the sub-models is examined while the conditions for the phenomenon of backward bifurcation are presented. A generalized analytical result of the COVID-19-influenza co-infection model is presented. We run a numerical simulation on the model without optimal control to see how competitive outcomes between-hosts and within-hosts affect disease co-dynamics. The findings established that disease competitive dynamics in the population are determined by transmission probabilities and threshold quantities. To obtain the optimal control problem, we extend the formulated model by including three time-dependent control functions. The maximum principle of Pontryagin was used to prove the existence of the optimal control problem and to derive the necessary conditions for optimum disease control. A numerical simulation was performed to demonstrate the impact of different combinations of control strategies on the infected population. The findings show that, while single and twofold control interventions can be used to reduce disease, the threefold control intervention, which incorporates all three controls, will be the most effective in reducing COVID-19 and influenza in the population.Entities:
Keywords: COVID-19; Co-infection; Influenza; Optimal control; Reproduction number
Year: 2022 PMID: 36106051 PMCID: PMC9461290 DOI: 10.1016/j.physa.2022.128173
Source DB: PubMed Journal: Physica A ISSN: 0378-4371 Impact factor: 3.778
Description of the model variables.
| Variable | Description |
|---|---|
| Population of susceptible individuals | |
| Population of individuals vaccinated against COVID-19 | |
| Population of individuals vaccinated against influenza | |
| Population of individuals vaccinated against COVID-19 and influenza | |
| Population of individuals exposed to COVID-19 only | |
| Population of individuals exposed to influenza only | |
| Population of individuals exposed to COVID-19 and influenza | |
| Population of COVID-19 asymptomatic infectious individuals | |
| Population of COVID-19 symptomatic infectious individuals | |
| Population of infectious individuals hospitalized for corona virus | |
| Population of influenza infectious individuals | |
| Population of COVID-19 and influenza infectious individuals | |
| Population of individuals recovered from COVID-19 | |
| Population of individuals recovered from influenza | |
| Population of individuals recovered from both COVID-19 and influenza |
The description of parameters and values.
| Parameter | Description | Value | Source |
|---|---|---|---|
| Recruitment rate of susceptible individuals | |||
| Infection modification parameter for the asymptomatic infection rate | 0.45 | ||
| Infection modification parameter for the hospitalized infection rate | 0.4509 | ||
| Transmission rate of COVID-19 | 0.5249 | ||
| Transmission rate of influenza | 0.203 | ||
| Vaccination rate against COVID-19 | 0.0203 | ||
| Vaccination rate against influenza | 0.00027375 | ||
| Vaccination rate against COVID-19 and influenza | 0.00027375–0.0203 | Assumed | |
| Immunity waning rate of recovered individuals with COVID-19 | 0.011 | ||
| Immunity waning rate of recovered individuals with influenza | 0.088 | ||
| Immunity waning rate of recovered individuals with co-infection | 0.011–0.088 | Assumed | |
| Vaccine waning rate of COVID-19 | 0.000297 | ||
| Vaccine waning rate of influenza | 0.15 | ||
| Vaccine waning rate of COVID-19 and influenza | 0.000297–0.15 | Assumed | |
| COVID-19 vaccine efficacy | 0.70 | ||
| Influenza vaccine efficacy | 0.77 | ||
| COVID-19 and influenza vaccine efficacy | 0.80 | Assumed | |
| COVID-19 progression rate from the exposed to either | 0.40 | ||
| asymptomatic or symptomatic infectious | |||
| Influenza progression rate from the exposed to infectious | 0.40 | ||
| co-infection progression rate from the exposed to infectious | 0.40 | Assumed | |
| Fraction of COVID-19 exposed individuals becoming symptomatic | 0.60 | ||
| Natural mortality rate | 0.0003516 | ||
| Death due to COVID-19 | 0.008 | ||
| Death due to influenza | 0.021 | ||
| Death due to co-infection | 0.021–0.026 | Assumed | |
| Hospitalization rate of symptomatic infectious individuals | 0.0624 | ||
| Recovery rate of COVID-19 asymptomatic infectious individuals | 0.13978 | ||
| Recovery rate of COVID-19 hospitalized infectious individuals | 0.125 | ||
| Recovery rate of influenza infectious individuals | 0.1998 | ||
| Recovery rate of co-infected infectious individuals | 0.125–0.1998 | Assumed | |
| Reduction of susceptibility to COVID-19 infection | 0.50 | Assumed | |
| Reduction of susceptibility to influenza infection | 0.50 | Assumed |
Fig. 1The schematic diagram of the co-infection model (2). The dotted line represents an extension of susceptible individuals, and the forces of infection , and for depiction convenience.
Fig. 2Simulation of model (2) showing the dynamics and final sizes of the total infected individuals when , with . Parameters are at baseline values except for . (a, b) COVID-19 has the within-host advantage , with (); (c, d) Influenza has the within-host advantage , with ().
Fig. 3Simulation of model (2) showing the dynamics and final sizes of the total infected individuals when , with . Parameters are at baseline values except for . (a, b) Influenza has the within-host advantage , with (); (c, d) COVID-19 has the within-host advantage , with ().
Fig. 4Simulations of the impact of control strategy A on (a) total COVID-19 infected people, (b) total influenza-infected people, and (c) total co-infected people.
Fig. 5Simulations of the impact of control strategy B on (a) total COVID-19 infected people, (b) total influenza-infected people, and (c) total co-infected people.
Fig. 6Simulations of the impact of control strategy C on (a) total COVID-19 infected people, (b) total influenza-infected people, and (c) total co-infected people.
Fig. 7Simulations of the impact of control strategy D on (a) total COVID-19 infected people, (b) total influenza-infected people, and (c) total co-infected people.
Fig. 8Simulations of the impact of control strategy E on (a) total COVID-19 infected people, (b) total influenza-infected people, and (c) total co-infected people.
Fig. 9Simulations of the impact of control strategy F on (a) total COVID-19 infected people, (b) total influenza-infected people, and (c) total co-infected people.
Fig. 10Simulations of the impact of control strategy G on (a) total COVID-19 infected people, (b) total influenza-infected people, and (c) total co-infected people.